Compare Stocks: SBFM, PPCB, CASI, and GRI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
GRI GRI Bio	$1.38 -2.1%	$1.84	$1.36 ▼ $80.36	$2.50M	-1.21	32,320 shs	23,212 shs
PPCB Propanc Biopharma	$1.01 -2.9%	$1.59	$0.95 ▼ $270.25	$2.37M	3.49	405,914 shs	39,274 shs
SBFM Sunshine Biopharma	$1.17 -4.9%	$2.20	$1.10 ▼ $24.30	$620K	1.13	110,178 shs	79,246 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	+0.00%	-86.35%
GRI GRI Bio	-2.13%	-4.83%	-22.47%	-36.70%	-97.60%
PPCB Propanc Biopharma	-2.88%	-26.28%	-29.86%	-60.89%	-99.57%
SBFM Sunshine Biopharma	-4.88%	-29.52%	-46.33%	-88.91%	-92.04%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CASI CASI Pharmaceuticals	$0.21	$0.21	$0.21 ▼ $3.09	$2.55M	0.91	482,532 shs	N/A
GRI GRI Bio	$1.38 -2.1%	$1.84	$1.36 ▼ $80.36	$2.50M	-1.21	32,320 shs	23,212 shs
PPCB Propanc Biopharma	$1.01 -2.9%	$1.59	$0.95 ▼ $270.25	$2.37M	3.49	405,914 shs	39,274 shs
SBFM Sunshine Biopharma	$1.17 -4.9%	$2.20	$1.10 ▼ $24.30	$620K	1.13	110,178 shs	79,246 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CASI CASI Pharmaceuticals	0.00%	0.00%	0.00%	+0.00%	-86.35%
GRI GRI Bio	-2.13%	-4.83%	-22.47%	-36.70%	-97.60%
PPCB Propanc Biopharma	-2.88%	-26.28%	-29.86%	-60.89%	-99.57%
SBFM Sunshine Biopharma	-4.88%	-29.52%	-46.33%	-88.91%	-92.04%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CASI CASI Pharmaceuticals	2.00	Hold	$4.00	1,827.71% Upside
GRI GRI Bio	2.00	Hold	$32.00	2,218.84% Upside
PPCB Propanc Biopharma	1.00	Sell	N/A	N/A
SBFM Sunshine Biopharma	2.00	Hold	$70.00	5,882.91% Upside

Current Analyst Ratings Breakdown

Latest SBFM, PPCB, CASI, and GRI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/29/2026	PPCB Propanc Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	GRI GRI Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SBFM Sunshine Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/1/2026	GRI GRI Bio	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $32.00
5/27/2026	SBFM Sunshine Biopharma	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
5/1/2026	PPCB Propanc Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CASI CASI Pharmaceuticals	$26.85M	0.10	N/A	N/A	$0.12 per share	1.73
GRI GRI Bio	N/A	N/A	N/A	N/A	$4.16 per share	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	$29.94 per share	N/A
SBFM Sunshine Biopharma	$36.31M	0.02	N/A	N/A	$46.93 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CASI CASI Pharmaceuticals	-$39.26M	-$3.01	N/A	N/A	N/A	-183.93%	N/A	-131.54%	N/A
GRI GRI Bio	-$11.96M	-$74.16	N/A	N/A	N/A	N/A	-199.52%	-143.23%	8/13/2026 (Estimated)
PPCB Propanc Biopharma	-$58.92M	-$24.25	N/A	N/A	N/A	N/A	-151.28%	-109.53%	N/A
SBFM Sunshine Biopharma	-$5.97M	-$12.90	N/A	N/A	N/A	-18.45%	-27.75%	-21.57%	8/11/2026 (Estimated)

Latest SBFM, PPCB, CASI, and GRI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GRI GRI Bio	-$1.20	N/A	N/A	N/A	N/A	N/A
8/11/2026	N/A	SBFM Sunshine Biopharma	-$1.20	N/A	N/A	N/A	$8.70 million	N/A
5/13/2026	Q1 2026	GRI GRI Bio	-$1.6050	-$1.61	-$0.0050	-$1.61	N/A	N/A
5/13/2026	Q1 2026	SBFM Sunshine Biopharma	-$1.60	-$0.25	+$1.35	-$0.25	$9.20 million	$8.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CASI CASI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GRI GRI Bio	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A
SBFM Sunshine Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CASI CASI Pharmaceuticals	N/A	0.30	0.24
GRI GRI Bio	N/A	14.20	14.21
PPCB Propanc Biopharma	N/A	2.37	2.37
SBFM Sunshine Biopharma	N/A	4.22	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CASI CASI Pharmaceuticals	22.23%
GRI GRI Bio	33.95%
PPCB Propanc Biopharma	N/A
SBFM Sunshine Biopharma	41.98%

Insider Ownership

Company	Insider Ownership
CASI CASI Pharmaceuticals	21.24%
GRI GRI Bio	8.73%
PPCB Propanc Biopharma	28.50%
SBFM Sunshine Biopharma	0.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CASI CASI Pharmaceuticals	180	12.30 million	9.69 million	Optionable
GRI GRI Bio	1	1.77 million	1.62 million	Not Optionable
PPCB Propanc Biopharma	1	2.28 million	1.63 million	Not Optionable
SBFM Sunshine Biopharma	3	500,000	499,000	Not Optionable

SBFM, PPCB, CASI, and GRI Headlines

Recent News About These Companies

Head-To-Head Contrast: Sunshine Biopharma (NASDAQ:SBFM) & Foghorn Therapeutics (NASDAQ:FHTX)

August 1 at 3:15 AM | americanbankingnews.com

Sunshine Biopharma Inc.: Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

July 30 at 7:49 AM | finanznachrichten.de

Health Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and Vomiting

July 28, 2026 | accessnewswire.comA

Sunshine Biopharma Inc.: Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

July 20, 2026 | finanznachrichten.de

Sunshine Biopharma and University of Arizona Publish Significant New Research Findings

July 20, 2026 | accessnewswire.comA

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)

June 25, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)

June 1, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

May 29, 2026 | accessnewswire.comA

Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing

May 28, 2026 | accessnewswire.comA

Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin

May 21, 2026 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering

May 19, 2026 | accessnewswire.comA

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

May 18, 2026 | accessnewswire.comA

SBFM Share News Today

May 15, 2026 | uk.investing.com

Sunshine Biopharma Delays Annual SEC Filing

April 14, 2026 | theglobeandmail.com

Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year

April 6, 2026 | accessnewswire.comA

Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)

October 28, 2025 | accessnewswire.comA

Sunshine Biopharma’s Nora Pharma receives Health Canada approval for domperidone

October 28, 2025 | msn.com

Sunshine Biopharma stock rises after Health Canada approval for Domperidone

October 28, 2025 | za.investing.com

Sunshine Biopharma Inc.: Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

October 28, 2025 | finanznachrichten.de

Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea

October 28, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SBFM, PPCB, CASI, and GRI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

$0.21 0.00 (0.00%)

As of 07/31/2026

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

GRI Bio NASDAQ:GRI

$1.38 -0.03 (-2.13%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$1.44 +0.06 (+4.13%)

As of 07/31/2026 07:55 PM Eastern

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

Propanc Biopharma NASDAQ:PPCB

$1.01 -0.03 (-2.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.98 -0.04 (-3.47%)

As of 07/31/2026 07:48 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Sunshine Biopharma NASDAQ:SBFM

$1.17 -0.06 (-4.88%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.12 -0.05 (-4.70%)

As of 07/31/2026 07:51 PM Eastern

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SBFM, PPCB, CASI, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SBFM, PPCB, CASI, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SBFM, PPCB, CASI, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SBFM, PPCB, CASI, and GRI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

GRI Bio NASDAQ:GRI

Propanc Biopharma NASDAQ:PPCB

Sunshine Biopharma NASDAQ:SBFM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SBFM, PPCB, CASI, and GRI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SBFM, PPCB, CASI, and GRI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SBFM, PPCB, CASI, and GRI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SBFM, PPCB, CASI, and GRI Company Descriptions

CASI Pharmaceuticals NASDAQ:CASI

GRI Bio NASDAQ:GRI

Propanc Biopharma NASDAQ:PPCB

Sunshine Biopharma NASDAQ:SBFM

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools